信達生物(01801.HK)與賽諾菲訂戰略合作 溢價發新股引資3億歐元
信達生物(01801.HK)公布,向創新醫藥健康企業賽諾菲發行合共5,697.56萬股新股,佔公司擴大後股本3.73%,總額3億歐元(約24.17億港元),相當於每股作價42.42元,較上交易日(4日)收報溢價29.13%。所得淨額24.15億元,將用於日常業務營運。
同時,雙方達成多項目戰略合作及許可協議,合作開展兩款高潛力抗腫瘤藥物SAR408701及SAR444245在中國的臨床開發及商業化。集團無需就協議支付任何首付款。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.